Prediction: Lilly Will Trade at $1,200 by Year-End
Investors weigh a bold forecast that Eli Lilly could hit $1,200 by year-end 2026, betting on GLP-1 drugs and a robust...
New to investing? Check out these zero fee investment apps designed specifically for new investors to start building wealth.
28,005 articlesInvestors weigh a bold forecast that Eli Lilly could hit $1,200 by year-end 2026, betting on GLP-1 drugs and a robust...
June’s jobs data surprised markets with a modest gain of 57,000 positions. Here’s how this surprising print could sha...
Small-cap stocks are delivering the sharpest outperformance versus the S&P 500 in years, with a roughly 20% YTD g...
Looking for a retirement spot near major culture and opportunities without NYC prices? This guide spotlights two nort...
CrossCountry Mortgage unveils a dedicated builder division to deepen relationships with builders and streamline finan...
A proposed bill could reshape how people finance homes by smoothing the path to loans for buying (and building) house...
XRP ETFs have seen a wave of redemptions in March, yet industry analysts say the funds’ resilience remains intact as ...
A fund’s big move out of a top-performing pharma stock can puzzle investors. Here’s a clear, practical look at what k...
A handful of female CFOs at major tech firms are directing the era’s biggest AI infrastructure push. This piece expla...
Agility Robotics is pursuing a SPAC merger to go public, a move that would crown it the first pure-play humanoid robo...
Stoneridge is navigating a pivotal year as auto production and tech content rise. This guide breaks down what to expe...
AST SpaceMobile is rebounding with a $1.2 billion contracted commitments milestone and expanding carrier partnerships...